Asthma is a chronic inflammatory disease of the airways in the lungs of children and adults.
The patient usually complains of shortness of breath, chest tightness and coughing with wheezing.
Goals of treatment are effective symptom control with minimal or no exacerbations, minimal or no nocturnal and daytime symptoms, no limitations on activities, minimal or no need for reliever treatment, and minimal adverse effects of medication.
Budesonide–formoterol demonstrates superiority over albuterol, when used on an as-needed treatment basis, for preventing exacerbations in adult patients with mild asthma, according to the results of the open-label Novel START trial.
The overall health and process outcomes in asthma appear to have improved in a public primary healthcare institution in Singapore, owing to the adoption of Chronic Care Model (CCM)—a multifaceted model of care aimed at making patients healthier and healthcare providers more satisfied and reducing cost savings, as reported in a recent study.
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
A 4-week treatment with nocturnal continuous positive airway pressure (CPAP) has failed to achieve a twofold suppression of airway reactivity (PC20) among children with moderate-to-severe asthma, a recent study has shown.
The use of magnesium supplements as an adjunct to standard asthma treatment in patients with mild-to-moderate disease confers no significant benefits apart from an improvement in forced expiratory volume in 1 second after 8 weeks of treatment, according to the results of a meta-analysis.
The interleukin (IL)-5 receptor α antibody benralizumab continues to show a safety profile similar to that observed in the preceding primary trials along with sustained efficacy through 2 years of treatment in patients with severe, uncontrolled asthma, according to the BORA* extension trial.
Abdominal obesity appears to be a significant risk factor for the incidence of late-onset asthma in women but not men, a study reports. Except for waist circumference, metabolic syndrome and its components are not related to the incidence of asthma in both sexes.
New drug applications approved by US FDA as of 01 - 15 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Assoc Prof Philip Eng, senior consultant respiratory physician at Mt Elizabeth Hospital in Singapore, shares his insights with Pearl Toh on diagnosing and managing pneumonia in the primary care setting.
Extended preloading of varenicline for 6 weeks before the target quit day (TQD) safely improves the efficacy of the prescription medication in facilitating smoking cessation at 12 weeks and at 6 months, according to a study presented at the American Thoracic Society (ATS) 2019 International Conference, held at Dallas, Texas in the US.